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The Structure of JNK3 in Complex
with Small Molecule Inhibitors: Structural
Basis for Potency and Selectivity
death was reported by Yang et al. [6] who showed that
JNK3-deficient mice were resistant to kanic acid-
induced excitotoxicity and associated apoptotic cell
death. Moreover, it has recently been shown that inhibi-
tors of JNK3 are neuroprotective against NGF-with-
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Merck Research Laboratories drawal-induced cell death of rat sympathetic neurons
[S.J. Harper, et al., 2002, FENS Forum, abstract; S.J.P.O. Box 2000
Rahway, New Jersey 07065 Harper, et al., 2002, Soc. Neurosci., abstract], as well
as against 1-methyl-4-phenylpyridinium-induced cell3 Department of Molecular Neuroscience
Merck Research Laboratories death of dopaminergic neurons [J.G. Bilsland, et al.,
2000, Fed. Eur. Neurosci., abstract]. Two other genes3535 General Atomics Court
San Diego, California 92121 encoding JNKs, Jnk1 and Jnk2, and at least ten different
splicing isoforms have been identified in mammalian
cells [7]. While JNK3 is selectively expressed in the brain
and to a lesser extent in the heart and in the testis, JNK1Summary
and JNK2 are widely expressed in a variety of tissues
[7–9]. Studies with KO mice indicate that, although lossThe c-Jun terminal kinases (JNKs) are members of
the mitogen-activated protein (MAP) kinase family and of the Jnk genes produces animals that are viable and
show no gross differences from wild-type animals, someregulate signal transduction in response to environ-
mental stress. Activation of JNK3, a neuronal-specific defects in T cell differentiation and proliferation, IL-2
production, and neuronal tube closure are associatedisoform, has been associated with neurological dam-
age, and as such, JNK3 may represent an attractive with the loss of the Jnk1/2 genes [10, 11]. For these
reasons, isoform selectivity is desirable for the develop-target for the treatment of neurological disorders. The
MAP kinases share between 50% and 80% sequence ment of safe compounds. Although the three isoforms
share more than 90% sequence identity, each one hasidentity. In order to obtain efficacious and safe com-
pounds, it is necessary to address the issues of po- been shown to bind to the same substrates with different
affinities [7], and small differences in primary sequencetency and selectivity. We report here four crystal struc-
tures of JNK3 in complex with three different classes are present in their putative substrate binding site [12].
The design of selective kinase inhibitors has been aof inhibitors. These structures provide a clear picture
of the interactions that each class of compound made challenging problem because the great majority of
known kinase inhibitors are ATP competitive and bindwith the kinase. Knowledge of the atomic interactions
involved in these diverse binding modes provides a to a highly conserved ATP binding pocket [13–18]. The
strong similarities among kinase ATP binding sitesplatform for structure-guided modification of these
compounds, or the de novo design of novel inhibitors makes the development of selective inhibitors very diffi-
cult. Furthermore, the widespread use of purine-basedthat could satisfy the need for potency and selectivity.
cofactors by a variety of human proteins raises serious
toxicity issues. Protein crystallography has provided aIntroduction
detailed view of the ATP binding site, revealing five dis-
tinct subsites with distinct chemical environments andA growing body of evidence implicates the c-jun path-
way, and particularly JNK3, in a variety of apoptotic local sequence features that afford an opportunity to
develop highly specific kinase inhibitors. The subsitesneuronal cell death scenarios. Rat sympathetic neurons
induced to die by nerve growth factor (NGF) deprivation are: (1) a hydrophobic adenine binding site in which
hydrogen bonds are made to nitrogen atoms of the ade-can be protected by microinjection of neutralizing anti-
bodies against c-jun [1] as well as by transfection of a nine ring; (2) a hydrophilic sugar pocket that enfolds
the ribose ring; (3) the solvent-exposed and hydrophilicdominant-negative form of c-jun [2]. More recently, the
phosphate binding region; (4) the hydrophobic region I,JNK pathway inhibitor CEP1347 has been shown to res-
a pocket adjacent to N7 of the adenine ring; and (5) thecue rat embryonic motoneurons deprived of NGF or
hydrophobic region II, a slot opening to solvent (Figureexposed to UV light or oxidative stress [3]. This com-
1) [14]. The two hydrophobic regions do not interactpound also shows protection against MPTP-induced
directly with bound ATP, but do contain residues thatnigrostriatal dopaminergic neuronal loss in a mouse
vary among kinases, and thus afford the medicinalmodel of Parkinson’s disease [4]. A similar result was
chemist opportunities to develop selective inhibitors. Asseen by Xia et al. [5] who showed that gene transfer of
shown by several examples [14, 19–23], knowledge ofthe JNK inhibitor JIP-1 protects dopaminergic neurons
the specific interactions made by an inhibitor in this siteagainst MPTP in a mouse model of Parkinson’s disease.
can lead to the design of highly selective compounds,Direct evidence linking JNK3 to apoptotic neuronal cell
despite the strong overall similarities among these pro-
teins.*Correspondence: giovanna_scapin@merck.com
In this report we present the three-dimensional struc-4 Present address: Avera Pharmaceuticals, 12730 High Bluff Drive,
Suite 160, San Diego, California 92130. tures of JNK3 with four compounds, representing three
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of NGF [S.J. Harper, et al., 2002, FENS Forum, abstract;
S.J. Harper, et al., 2002, Soc. Neurosci., abstract; J.G.
Bilsland, et al., 2000, Fed. Eur. Neurosci., abstract], and
thus hold promise as agents that may protect against
neurodegeneration induced by multiple stimuli. They
cannot be useful therapeutic agents, however, because
both compounds are also potent p38 inhibitors (with
IC50s of 0.2 and 4 nM, respectively) and do not show
any JNK isoform selectivity.
Compound 3 is a relatively weak JNK3 inhibitor (IC50 
590 nM) but shows no p38 inhibition for concentrations
up to 40 M. Compound 4 (SP600125) [26] is a moreFigure 1. Schematic Representation of the ATP Binding Site in Ki-
potent JNK3 inhibitor (IC50  150 nM) than compoundnases
3 and still shows no inhibition of p38 (IC50  30 M) [26]ATP (in ball-and-sticks) interacts mainly with the linker/adenine
(Figure 2A). Both compounds have been tested in ourbinding region (1), the ribose binding region (2), and the phosphate
binding region (3). The two hydrophobic regions I (4) and II (5) do laboratory against a panel of protein kinases, and the
not directly interact with ATP and contain residues that vary among results show that they are selective for JNK3 over a
kinases, thus providing possibilities for the development of selective variety of other enzymes, including several protein tyro-
inhibitors [17]. Figures 1, 2B, and 3–6 were made with RIBBONS [42]. sine kinases (data not shown). Similar to the diarylimida-
zole inhibitors, compounds 3 and 4 show no JNK isoform
selectivity.
distinct structural classes. Two of these compounds
display significant selectivity in inhibition of p38 and
JNK3 and two do not. Our results reveal the details of Structure of JNK3:Compound 1
how these three classes of inhibitors interact with JNK3 The structure of unphosphorylated JNK3 in complex
as well as how the selective compounds distinguish that with an ATP analog was originally reported in 1998 [27],
target from the closely related p38 kinase. We have and the structure reported here is substantially identical,
found that: (1) inhibitors represented by the structural with an rmsd on C atoms of 0.61 A˚. The catalytic do-
class of compound 3, and compound 4 (SP600125) are main comprises an N-terminal domain spanning resi-
selective JNK inhibitors with potencies 20-fold and 265- dues 45–149 and 379–400, and a C-terminal domain
fold greater than that for p38, respectively; (2) the in- spanning residues 150–211 and 217–374. Residues 212–
creased potency of compound 2 relative to compound 216 (part of the activation loop) were not visible in elec-
1 against JNK3 is apparently due to interactions of its tron density maps and were not included in the model.
cyclohexyl ring with hydrophobic region II; (3) the selec- As expected, compound 1 binds in the ATP binding site
tivity of compound 3 for JNK3 versus p38 is probably (Figure 2B). The bound inhibitor makes two hydrogen
due to the small, flat nature of this molecule and to bond interactions with the protein, involving the main
its interaction with Gln155 in JNK3; and (4) the higher chain nitrogen and oxygen atoms of Met149 (3.0 and
selectivity of compound 4 (SP600125) arises from its 3.2 A˚, respectively) in the linker region. The hydrogen
small size and flat shape that enable hydrophobic in- bond to the main chain nitrogen mimics the hydrogen
teractions that are not available in the larger, more hy- bond made by ATP, and it has been shown in kinases
drophilic p38 binding pocket. Taken together, these in general to be essential for inhibitor binding [14, 28]; the
structures provide useful insights into the further devel- presence of a second hydrogen bond has been directly
opment of MAP kinase family- and JNK isoform-selec- related to the significant increases in potency observed
tive inhibitors. for such compounds [19, 24]. The dichlorophenyl moiety
is bound in hydrophobic region I [14] (Figure 1), a pocket
lined by the side chains of Ala91, Lys93, Leu206, Ile124,Results and Discussion
Ile126, Leu144, and Met146, and the main chain atoms
of Leu144-Met146 and Ala91-Lys93. Comparison of theNovel JNK3 Inhibitors
The structures of four JNK3 inhibitors are given in Figure JNK3:compound 1 complex to the JNK3:AMP-PNP
complex (1JNK [27]) reveals only one notable conforma-2A. The crystal structures of JNK3 with each of these
compounds were solved by X-ray diffraction analysis tional difference: the Met146 side chain adopts a differ-
ent conformation, moving about 3 A˚ toward the backand refined to atomic resolution. Compounds 1 and 2
belong to the diarylimidazole family of MAP kinase inhib- of the ATP binding site in order to accommodate the
inhibitor. The cyclopropyl moiety of compound 1 is bounditors [24]. They are members of a family of MAP-kinase
inhibitors that bind strongly to p38 [24], but not to the in the so-called hydrophobic pocket II [14] (Figure 1),
within van der Waals distance of the side chains of Ile70,extracellular regulated kinase (ERK), and site-directed
mutagenesis experiments on ERK have revealed many Ile148, Asn152, Gln155, and Val196, and the main chain
atoms of residues 150–153. The piperidine ring of theof the structural features that account for the inability
of p38 inhibitors to bind to this kinase [25]. Compounds inhibitor occupies the phosphate binding area, in nonco-
valent contact with the glycine-rich loop (Gly71-Val78).1 and 2 are also potent JNK3 inhibitors with IC50s of 7
and 1 nM, respectively (Figure 2A). They are efficacious The piperidine ring is quite solvent exposed; several
water molecules can be seen in this area, although onlyin promoting neuronal survival of dopaminergic neurons
exposed to MPP, and sympathetic neurons deprived one (Wat673) interacts directly with the bound inhibitor.
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Figure 2. Chemical Structures and Binding
Mode for JNK3 Inhibitors
(A) Chemical structure and IC50 for the four
JNK3 inhibitors described in the text.
(B) Stereo view of compound 1 bound to the
ATP binding site of JNK3. The hydrogen bond
interactions made with the main chain of
Met149 are shown as red dotted lines. Other
key active site residues are noted.
Comparison of the structures of the JNK3:compound we now have cocrystals of p38 with other inhibitors
(G.S., unpublished data), which show that the p38 struc-1 complex and of p38 in complex with an analog of
compound 1 [29] (PDB code 1OUK) reveals regions of ture does not change dramatically upon inhibitor bind-
ing. In addition, the structure of the JNK3 complex withsimilarity and diversity in the ATP binding pocket that
may help in the design of compounds selective for either compound 3 reported here was obtained via a cocrystal-
lization experiment, and it is essentially identical to theenzyme. JNK3 and p38 share 51% identity in primary
sequence. Their three-dimensional structures are also three structures obtained by soaking. It is then reason-
able to expect that the relative shape and size of theextremely similar, although the relative orientations of
their N- and C-terminal domains are different, as pre- binding cavities will be maintained upon ligand binding,
thus suggesting that it is meaningful to examine theseviously observed [27]. Despite the different orientation,
the structures of the individual domains are quite similar, structures in order to understand the structural bases
of selectivity.with rmsds of 1.28 and 1.45 A˚ for the N- and C-terminal
domains, respectively. Before comparing the structures Figure 3 is a comparison between the JNK3 and p38
ATP binding sites. Panel A is a schematic view of com-in detail, however, it is worth considering whether the
different domain orientation may be an artifact caused pound 1 bound to JNK3; highlighted in the figure, and
listed to the right, are the residues in or near the ATPby the fact that the JNK3 structures were obtained in
presence of ATP analogs (displaced during soaks by binding site that are different between JNK3 and p38.
Four of the six nonconserved residues (between JNK3the higher affinity ligands), while the p38 structure used
in the comparison was not. Additional reservations arise and p38) are smaller in p38, meaning that p38 can ac-
commodate larger inhibitors that would not be effectivebecause the p38 complex was obtained by soaking the
inhibitor into a crystal of the apoprotein, and this proce- against JNK3. In addition, the different relative orienta-
tions of the N- and C-terminal domains in the two en-dure might have introduced biases (because of crystal
lattice contacts, or preorganized structures) that could zymes make the ATP binding pocket wider in p38 than
in JNK3 (Figures 3B and 3C). Indeed, a number of site-partially obscure the real interactions between a protein
and its ligand. Two key observations suggest that these directed mutagenesis studies on p38 where Thr106 in
p38 was mutated to the corresponding residue in JNK3issues do not preclude meaningful comparisons of the
available JNK3 and p38 structures. First, although there (Met) or ERK2 (Gln) have shown that this residue contrib-
utes significantly to the selectivity of many p38 inhibitorsare no structures available for apo-JNK3, several struc-
tures are available for p38 complexes, and they show [19, 30, 31]. This analysis suggests that small, flat inhibi-
tors that do not reach into pockets conferring p38 speci-that the structures of the complexed and uncomplexed
enzyme are essentially identical [19, 29. 30]. Second, ficity, but do rely mostly on hydrophobic interactions
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Although compound 2 belongs to the same class of
inhibitors as compound 1, and thus shares its liabilities,
the crystal structure of JNK3 in complex with compound
2 reveals a striking and possibly useful new feature that
could be used to discriminate among the different JNK
isoforms. As mentioned before, the structure of com-
pound 2 bound to JNK3 was obtained by overnight soak-
ing of the compound into crystals grown in AMP-PCP.
During refinement, it was clear that in both 2Fo-Fc and
Fo-Fc Fourier maps there was a continuous residual
positive electron density near the bound inhibitor that
could not be attributed to protein or inhibitor atoms.
The electron density was fitted as AMP-PCP, complexed
to the N-4-piperydil nitrogen of the compound (Figure
4). The AMP-PCP is not in the canonical ATP binding
site, as found in the 1JNK structure, which is occupied
by the inhibitor. Rather, the AMP-PCP molecule is hydro-
gen bonded to the N-4-piperidyl nitrogen of compound
2, and extends toward the putative protein binding site
[9], where it makes several hydrogen bond interactions
to protein and solvent atoms. The adenine interacts with
Glu255 and Ile261 in the putative substrate binding do-
main (Ile246-Tyr268), which is the region that displays
the greatest diversity among JNKs isoforms. This un-
usual complex suggests a means of designing bidentate
inhibitors that extend from the ATP binding pocket to-
ward the substrate binding area, thus enabling the de-
sign of very selective kinase inhibitors [32] that may also
address the issue of isoform selectivity.
Structure of JNK3:Compound 3
Figure 3. Comparison of the ATP Binding Sites in JNK3 and p38 Compound 3 (Figure 2A) is a 590 nM JNK inhibitor, with
(A) Schematic view of compound 1 bound to JNK3. Possible interac- no detectable p38 activity up to 40 M. The compound
tions are indicated by the dashed lines. Highlighted in the figure, was discovered by screening the Merck compound col-
and listed to the right, are the residues in or near the ATP binding lection, and has a structure strikingly different from mostsite that are different between JNK3 and p38.
previously described kinase inhibitors. Although a rela-(B) Surface representation of the ATP binding site in p38.
tively weak inhibitor, compound 3 is small and thus suit-(C) Surface representation of the ATP binding site in JNK3.
able for chemical modifications that may improve both
potency and selectivity, and those modifications can be
guided by our results. Crystals of this compound werefor binding, would be JNK3 specific. This idea is borne
out by compounds 3 and 4 (below). obtained by cocrystallization, under conditions similar
to that of the AMP-PCP complex originally reported.
Compound 3 is bound in a portion of the ATP bindingStructure of JNK3:Compound 2
Compound 2 binds to JNK3 essentially as compound 1 site (Figure 5) comprising the adenine binding pocket
and hydrophobic region II. The inhibitor makes four hy-does. This compound is 7-fold more potent than com-
pound 1; the increase in potency is probably due to the drogen bonds: one with the linker region (main chain
nitrogen of Met149, 2.5 A˚), two with the side chain ofreplacement of the cyclopropyl ring with a cyclohexyl
ring. The larger ring optimizes interactions with the side Gln155 (2.6 and 3.0 A˚, respectively), and one with the
main chain nitrogen of Gln75 (2.9 A˚). Gln155 corre-chains of Ile70 (4.2 A˚ in complex 2 versus 5.4 A˚ in com-
plex 1), Ile148 (5.1 versus 5.7 A˚), Asn152 (4.0 versus sponds to Asn115 in p38, and given the different orienta-
tion of the two kinase lobes and the smaller size of5.4 A˚) and Gln155 (3.4 versus 4.3 A˚). This last contact
also suggests that introducing a polar contact by, for asparagine, its side chain would be about 5.8 A˚ away
from the ligand in a comparable p38 complex. There areexample, using a piperidine in this position may improve
potency. Gln155 corresponds to Asn115 in p38, and, as no other residues nearby in p38 that could provide an
interaction similar to that seen in JNK3; Gln155 may thusdiscussed below, the smaller residue in p38 may be
useful in obtaining discrimination between JNK3 and play a critical role in the selectivity of compound 3 for
JNK3 over p38. Another reason for the observed selec-p38. Comparison between the structures of compound
1- and compound 2-bound JNK3 suggests that it could tivity is that compound 3 is a small, flat, hydrophobic
molecule that, as suggested before, probably binds bet-be possible to target selectivity by modifying this class
of compounds to take advantage of the small differ- ter to the smaller JNK3 site than to the wider and more
solvent-exposed p38 cavity.ences between the two enzymes without a major loss
in potency. The interaction with the main chain nitrogen of Gln75
JNK3 Structure in Complex with Potent Inhibitors
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Figure 4. Stereoview of the ATP Binding Site
in the JNK3:Compound 2 Complex, Showing
the Location of the AMP-PCP Molecule that
Was Found in the Structure
The 2Fo-Fc electron density (contoured at 1.0
s) for both compound 2 and AMP-PCP is also
displayed. The AMP-PCP was hydrogen
bonded to the N-4-piperidyl nitrogen of com-
pound 2, and extended toward the putative
substrate binding domain (I246-Y268) [9].
is made possible by a dramatic change in the conforma- of the glycine-rich loop spanning residues Ile70-Ile77
bends almost 90 away from the position observed intion of the Gly-rich loop, the flap that in all kinases covers
the phosphate binding region of the ATP binding site. complex 1. This region of the protein kinases is very
flexible, and a ligand-induced conformational changeFigure 5A shows the C trace of JNK3:compound 1
superimposed on the compound 3 complex; a portion similar to the one observed here has been reported
Figure 5. Binding of Compound 3 to JNK3
(A) Overlay of the C traces of JNK3:com-
pound 1 (magenta) and JNK3:compound 3
complexes (yellow) in the region of the gly-
cine-rich loop (G71-V78). The conformational
change observed for residues Ile70–Ile77 was
ligand induced.
(B) Close-up of the compound 3 binding site;
hydrogen bond interactions with protein
atoms are shown as blue dotted lines.
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Figure 6. Close-Up of the Binding Site in the
JNK3:Compound 4 Complex: the Two Panels
Represent Two Views 90 Apart
The residues that are not conserved in p38
and thus responsible for the selectivity for
JNK3 over p38 displayed by this compound
are shown as thick ball-and-stick.
for the tyrosine kinase domain of the fibroblast growth cannot fully form these productive hydrophobic interac-
tions (Figures 3A, 3B, and 6). In addition, based on thefactor receptor 1 in complex with SU5402 [33]. The se-
quences of p38 and JNK3 are basically identical in the structure of the JNK3:compound 3 complex, it is appar-
ent that suitable modifications of compound 4 couldGly-rich loop, with the only difference being a Gln to Tyr
mutation at position 75 (residue 35 in p38). The inhibitor allow for interactions with Gln155 with possible increase
in both potency and selectivity.interacts only with the main chain atoms of this residue,
so they should not be affected by the difference in se-
quence. In addition, a similar loop movement has been Significance
observed in p38 upon binding of one of our compounds
(G.S., unpublished data), suggesting that this loop The c-Jun terminal kinases (JNKs) are members of the
movement is not a primary cause of the selectivity of MAP kinase family and regulate signal transduction in
compound 3 for JNK3 over p38. response to environmental stress. Activation of JNK3,
a neuronal-specific isoform, has been associated with
Structure of JNK3:Compound 4 (SP 600125) neurological damage, and as such, JNK3 may represent
Compounds in this class were originally identified as an attractive target for the treatment of neurological
JNK3 inhibitors by Signal Pharmaceutical (now part of disorders. Although the discovery of selective kinase
Celgene); we identified compound 4 (SP600125) by inhibitors has been a challenging problem because the
screening of our compound collection. Compound 4 great majority of known kinase inhibitors bind to the
inhibits JNK1 and -2 with an IC50 of 110 nM, and JNK3 highly conserved ATP binding pocket, knowledge of
with an IC50 of 150 nM, but is much less active on p38, the specific interactions made by a compound in this
with an IC50  30 M [26], which makes it, to our knowl- site can lead to the design of highly selective com-
edge, the most selective JNK3 inhibitor available. As pounds. In this report we present the three-dimen-
with compounds 1 and 2, the complex of JNK3 with sional structures of JNK3 in complex with four com-
compound 4 was obtained by soaking an AMP-PNP- pounds, representing three distinct structural classes.
containing crystal overnight in a 1 mM solution of inhibi- The compounds range in potency between 1 and 590
tor. The electron density for the inhibitor was quite clear nM, and display different selectivity in inhibition of p38
in the ATP binding site. Compound 4 makes hydrogen and JNK3. Our results reveal the details of how these
bonds with the carbonyl oxygen of Glu147 (2.8 A˚) and three classes of inhibitors interact with JNK3 as well as
the main chain nitrogen of Met149 (2.8 A˚) in the linker how the selective compounds distinguish this target
region (Figure 6). These two interactions are similar to from the closely related p38 kinase. The structures
those formed by compounds 1 and 2 and may explain show that potency can be achieved by specific interac-
why the relatively small compound 4 is nevertheless tions with residues of the ATP binding site. In addition,
quite potent. The selectivity for JNK3 over p38 likely we show that small, flat, hydrophobic molecules inter-
arises because the inhibitor is, like compound 3, within act preferentially with JNK3 and afford considerable
van der Waals distance from several residues that line selectivity over p38. Knowledge of the atomic interac-
the ATP binding site (4.1 A˚ from Ile70, 4.3 A˚ from Val78, tions revealed by our studies may provide a platform
4.2 A˚ from Ile124, 3.8 A˚ from Val196, and 3.8 A˚ from for the further development of MAP kinase family- and
Leu206, Figure 6). Most of these residues are not con- JNK isoform-selective inhibitors that could satisfy the
served in p38, and even if conserved would be farther need for potency against JNK3 and selectivity against
from the inhibitor, i.e., Ile70 corresponds to a valine, other protein kinases.
whose side chain would be 5.2 A˚ from the bound inhibi-
Experimental Procedurestor, and Val196 to an alanine (6.5 A˚ away). Val78, Ile124,
and Leu206 are conserved, but their distance from the
Cloning and Expressioninhibitor would be increased to 4.5, 4.8, and 4.5 A˚, re-
JNK3 was cloned and expressed as described in Lisnock et al. [34]
spectively. This analysis indicates that compound 4,
which is small, flat, hydrophobic, and relies largely on Purification and Crystallization
hydrophobic interactions for binding, finds in JNK3 an JNK3 was purified following the published protocol [27]. The protein
was initially stored in 25 mM HEPES, pH 7.0, 2.5% glycerol, 50 mMoptimized environment, while the larger cavity in p38
JNK3 Structure in Complex with Potent Inhibitors
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Table 1. Statistics for the Data Sets Used to Solve the Structures of the Complexes Described in the Paper and Final Statistics for
the Refined Models
Compound 1a Compound 2b Compound 3a Compound 4b
UCP (A˚) a  53.07 A˚ a  50.95 A˚ a  62.40 A˚ a  48.21 A˚
b  71.34 A˚ b  71.53 A˚ b  62.38 A˚ b  73.09 A˚
c  107.17 A˚ c  106.00 A˚ c  98.12 A˚ c  106.04 A˚
Resolution range (A˚) 22.0–2.2 (2.3–2.2) 17.0–2.2 (2.3–2.2) 25.0–2.7 (2.8–2.7) 30.0–2.5 (2.6–2.5)
No. reflections 21,026 (3,431) 19,487 (1,594) 10,987 (1,668) 12,783 (1,086)
% of possible 98.6 (98.5) 95.6 (80.1) 100 (100) 94.4 (81.1)
Redundancy 6.1 (5.8) 7.8 (7.6) 5.9 (6.2) 5.5 (5.8)
I/I 8.6 (2.4) 10.0 (3.0) 5.7 (1.3) 7.0 (1.4)
Rsym 5.9 (19.7) 6.1 (17.7) 12.3 (45.4) 7.2 (34.1)
Refinement Statistics
Resolution range (A˚) 22.0–2.2 17.0–2.2 25.0–2.7 30.0–2.5
No. of reflectionsc 21,014 19,386 10,496 12,750
% of possible 98.6 95.7 95.5 94.3
Rfree/R 26.6/22.8 26.2/22.8 28.5/21.8 28.2/21.8
Rmsd bond length/angle 0.012/1.47 0.011/1.4 0.011/1.42 0.011/1.24
No. of protein atoms 2777 2805 2752 2787
No. of solvent atoms 197 55 63 101
No. of ligand atoms 33 66 22 19
Numbers in parentheses refer to last resolution shell.
a Integration, scaling, and merging of the data were done using X-GEN [40].
b Integration, scaling, and merging of the data were done using HKL2000 [41].
c No  cut off was used during refinement.
NaCl, 10 mM DTT, but dynamic light scattering analysis indicated for data between 8 and 4 A˚. Analysis of crystal packing showed
that there were some severe steric clashes involving residues 210–that the protein was severely polydisperse. Several buffer conditions
were then tried in order to obtain a monodisperse solution of protein: 227 and 365–384. These residues were omitted during the initial
refinement, and slowly built back into the available density. Residuesthe best buffer was 20 mM HEPES, pH 7.0, 50 mM NaCl, 0.02%
n-octyl-glucopyranoside, 5 mM TCEP. Crystals of the JNK3:AMP- 70–76 (of the Gly-rich loop) were also omitted and rebuilt at a later
stage. Volunteer electron density for the bound inhibitor was avail-PCP complex were obtained by vapor diffusion in hanging drops:
the enzyme (10 mg/ml protein in buffer containing 1 mM AMP-PCP able since the initial map, but compound 3 was included in the
model at a much later stage. The refinement of this complex wasand 2 mM MgCl2) was equilibrated at room temperature against a
reservoir containing 20% PEG MME 550, 10% ethylene glycol in 0.1 carried out essentially as for the previous complexes. Table 1 sum-
marizes the final statistics for all four complexes.M HEPES, pH 7.3. Crystals of the compound 1, 2, and 4 complexes
were obtained by soaking the AMP-PCP-containing crystals over-
night in 1 mM compound in mother liquor. Crystals of the compound Acknowledgments
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